Abstract
Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Current Pharmaceutical Design
Title: New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways
Volume: 15 Issue: 14
Author(s): Akira Nishida, Tsuyoshi Miyaoka, Takuji Inagaki and Jun Horiguchi
Affiliation:
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Abstract: Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Export Options
About this article
Cite this article as:
Nishida Akira, Miyaoka Tsuyoshi, Inagaki Takuji and Horiguchi Jun, New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways, Current Pharmaceutical Design 2009; 15 (14) . https://dx.doi.org/10.2174/138161209788168065
DOI https://dx.doi.org/10.2174/138161209788168065 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Differential Modulation of TNfα -Induced Cell Death By 3-Methyladenine, an Autophagy Inhibitor
Letters in Drug Design & Discovery Phenylpyazoleanilides as a Potent Inhibitor of IL-15 Dependent T Cell Proliferation. Part 1: A New Class of Orally Available Immunomodulators
Letters in Drug Design & Discovery Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment
Current Pharmaceutical Design A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Leptin and Vascular Smooth Muscle
Current Vascular Pharmacology Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Subject Index to Volume 4
Current Protein & Peptide Science Intestinal Epithelial Barrier Dysfunction in Disease and Possible Therapeutical Interventions
Current Medicinal Chemistry Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Immunomodulatory Effect of G2013 (α-L-Guluronic Acid) on the TLR2 and TLR4 in Human Mononuclear Cells
Current Drug Discovery Technologies Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Artificial Neural Networks for the Prediction of Response to Interferon Plus Ribavirin Treatment in Patients with Chronic Hepatitis C
Current Pharmaceutical Design Nitric Oxide (NO) System in Major Depression: Studies on NO Synthase Inhibitors as Antidepressant Agents
Current Enzyme Inhibition Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Redox Mechanisms of Vascular Cell Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Cannabinoids and Psychosis
Current Pharmaceutical Design Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry